Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice - Episode 2

Frontline Quadruplet Therapy in NDMM: GMMG-HD7

May 10, 2022

Shaji Kumar, MD, Morie A. Gertz, MD, MACP, David Dingli, MD, PhD, Prashant Kapoor, MD

Shared insight on the GMMG-HD7 study, which utilized a frontline isatuximab-containing quadruplet regimen in patients with newly diagnosed multiple myeloma.

EP. 1: Frontline Quadruplet Therapy in NDMM: GRIFFIN and MASTER Studies

Now Viewing

EP. 2: Frontline Quadruplet Therapy in NDMM: GMMG-HD7

EP. 3: NDMM Management: Assessing Response and Determining Duration of Therapy

EP. 4: Case Presentation 1: Selecting Therapy in Transplant-Ineligible NDMM